Showing results (221-230 of 258) with videos related to

Sort By:
Pageof 26
Journal of Translational Medicine|January 14, 2012
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyGeorge Fountzilas, Christos Valavanis, Vassiliki Kotoula, et al.
Breast Cancer Research and Treatment|March 22, 2012
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFlorentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou, et al.
Breast Cancer Research and Treatment|March 16, 2006
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyIoannis Kostopoulos, Petroula Arapantoni-Dadioti, Helen Gogas, et al.
BMC Cancer|February 5, 2013
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypesGeorge Pentheroudakis, Vassiliki Kotoula, Wendy De Roock, et al.
Anticancer Research|May 29, 2017
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant ChemotherapyTheofani Gavressea, Konstantine T Kalogeras, Georgia-Angeliki Koliou, et al.
Anticancer Research|May 7, 2017
Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast CancerTitika-Marina Strati, Vassiliki Kotoula, Ioannis Kostopoulos, et al.
Clinical Breast Cancer|November 9, 2019
The Role of CXCL13 and CXCL9 in Early Breast CancerEvangelia Razis, Konstantine T Kalogeras, Ioannis Kotsantis, et al.
Breast Cancer Research and Treatment|December 22, 2011
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialHelen Gogas, Urania Dafni, Maria Karina, et al.
American Journal of Cancer Research|January 27, 2017
The fate of BRCA1-related germline mutations in triple-negative breast tumorsVassiliki Kotoula, Florentia Fostira, Kyriaki Papadopoulou, et al.
Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Pageof 26